Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Acrivon Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Acrivon Therapeutics, Inc.’s stock price such as:

• Acrivon Therapeutics, Inc.’s current stock price and volume
• Why Acrivon Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ACRV from analysts
• ACRV’s stock price momentum as measured by its relative strength

About Acrivon Therapeutics, Inc. (ACRV)

Before we jump into Acrivon Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Want to learn more about Acrivon Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Acrivon Therapeutics, Inc..

Acrivon Therapeutics, Inc.’s Stock Price as of Market Close

As of April 21, 2026, 4:00 PM, CST, Acrivon Therapeutics, Inc.’s stock price was $1.760.

Acrivon Therapeutics, Inc. is down 5.38% from its previous closing price of $1.860.

During the last market session, Acrivon Therapeutics, Inc.’s stock traded between $1.750 and $1.870. Currently, there are approximately 38.66 million shares outstanding for Acrivon Therapeutics, Inc..

Acrivon Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Acrivon Therapeutics, Inc. Stock Price History

Acrivon Therapeutics, Inc.’s (ACRV) price is currently up 26.62% so far this month.

During the month of April, Acrivon Therapeutics, Inc.’s stock price has reached a high of $1.950 and a low of $1.360.

Over the last year, Acrivon Therapeutics, Inc. has hit prices as high as $3.560 and as low as $1.050. Year to date, Acrivon Therapeutics, Inc.’s stock is down 26.97%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Acrivon Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 21, 2026, there was 1 analyst who downgraded Acrivon Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Acrivon Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Acrivon Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Acrivon Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Acrivon Therapeutics, Inc. (ACRV) by visiting AAII Stock Evaluator.

Relative Price Strength of Acrivon Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 21, 2026, Acrivon Therapeutics, Inc. has a weighted four-quarter relative price strength of -8.11%, which translates to a Momentum Score of 28 and is considered to be Weak.

Want to learn more about how Acrivon Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Acrivon Therapeutics, Inc. Stock Price: Bottom Line

As of April 21, 2026, Acrivon Therapeutics, Inc.’s stock price is $1.760, which is down 5.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Acrivon Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.